Cue Biopharma Secures $7.5M Milestone From Boehringer Ingelheim For Advancing Autoimmune Therapy Development

Cue Biopharma, Inc. has announced that it will receive a $7.5 million preclinical milestone payment from Boehringer Ingelheim. The payment follows Boehringer Ingelheim’s selection of a candidate molecule for lead optimization under their ongoing collaboration and license agreement, with funds expected to be received in May 2026.

The partnership leverages Cue Biopharma’s proprietary platform, which is designed to selectively engage memory T cell subsets to target and deplete pathogenic B cells. This approach has potential applications in treating autoimmune and inflammatory diseases, representing a novel direction in biologic drug development.

“We are very pleased to have achieved this critical preclinical milestone through our strategic research collaboration with Boehringer Ingelheim,” said Lucinda Warren, interim president and chief executive officer of Cue Biopharma. “This is a very exciting time for the Company as we progress our lead autoimmune asset, CUE-401, toward the clinic and reach this important milestone in our collaboration with Boehringer Ingelheim to further develop CUE-501, a bispecific molecule intended for autoimmune and inflammatory diseases.”

Beyond this milestone, the collaboration includes provisions for expanding research into additional B cell-targeting bispecific therapies. This could broaden the scope of the partnership across multiple autoimmune disease indications, further advancing innovative therapeutic strategies.

Under the agreement terms, Cue Biopharma remains eligible to receive up to approximately $337.5 million in additional milestone payments tied to research, development, and commercialization, along with royalties on future product sales. This highlights the collaboration's long-term value and potential.